Table 5 Correlations between the expression of sarcosine metabolism-related proteins and clinicopathologic parameters
Parameter | GNMT | SARDH | PIPOX in tumor | PIPOX in stroma | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Negative n =664 (%) | Positive n = 57 (%) | P-value* | Negative n =597 (%) | Positive n = 124 (%) | P-value* | Negative n = 570 (%) | Positive n = 151 (%) | P-value* | Negative n = 671 (%) | Positive n =50 (%) | P-value* | |
Age (years) | Â | Â | 0.588 | Â | Â | 0.336 | Â | Â | 0.620 | Â | Â | 1.088 |
  ≤50 | 389 (58.6) | 39 (68.4) |  | 363 (60.8) | 65 (52.4) |  | 346 (60.7) | 82 (54.3) |  | 402 (59.9) | 26 (52.0) |  |
  >50 | 275 (41.4) | 18 (31.6) |  | 234 (39.2) | 59 (47.6) |  | 224 (39.3) | 69 (45.7) |  | 269 (40.1) | 24 (48.0) |  |
Histologic grade | Â | Â | 1.128 | Â | Â | 3.068 | Â | Â | 3.036 | Â | Â | 1.024 |
  I/II | 443 (66.7) | 42 (73.7) |  | 403 (67.5) | 82 (66.1) |  | 385 (67.5) | 100 (66.2) |  | 455 (67.8) | 30 (60.0) |  |
  III | 221 (33.3) | 15 (26.3) |  | 194 (32.5) | 42 (33.9) |  | 185 (32.5) | 51 (33.8) |  | 216 (32.2) | 20 (40.0) |  |
Tumor stage | Â | Â | 0.376 | Â | Â | 1.316 | Â | Â | 0.308 | Â | Â | 3.644 |
  T1 | 333 (50.2) | 22 (38.6) |  | 289 (48.4) | 66 (53.2) |  | 271 (47.5) | 84 (55.6) |  | 330 (49.2) | 25 (50.0) |  |
  T2/T3 | 331 (49.8) | 35 (61.4) |  | 308 (51.6) | 58 (46.8) |  | 299 (52.5) | 67 (44.4) |  | 341 (50.8) | 25 (50.0) |  |
Nodal metastasis | Â | Â | 2.116 | Â | Â | 3.640 | Â | Â | 2.604 | Â | Â | 2.524 |
  Absent | 391 (58.9) | 36 (63.2) |  | 353 (59.1) | 74 (59.7) |  | 340 (59.6) | 87 (57.6) |  | 399 (59.5) | 28 (56.0) |  |
  Present | 273 (41.1) | 21 (36.8) |  | 244 (40.9) | 50 (40.3) |  | 230 (40.4) | 64 (42.4) |  | 272 (40.5) | 22 (44.0) |  |
Estrogen receptor status | Â | Â | 0.060 | Â | Â | 3.644 | Â | Â | 1.672 | Â | Â | 2.132 |
  Negative | 247 (37.2) | 12 (21.1) |  | 215 (36.0) | 44 (35.5) |  | 209 (36.7) | 50 (33.1) |  | 239 (35.6) | 20 (40.0) |  |
  Positive | 417 (62.8) | 45 (78.9) |  | 382 (64.0) | 80 (64.5) |  | 361 (63.3) | 101 (66.9) |  | 432 (64.4) | 30 (60.0) |  |
Progesterone eceptor status | Â | Â | 0.004 | Â | Â | 1.572 | Â | Â | 0.204 | Â | Â | 3.020 |
  Negative | 330 (49.7) | 17 (29.8) |  | 283 (47.4) | 64 (51.6) |  | 285 (50.0) | 62 (41.1) |  | 324 (48.3) | 23 (46.0) |  |
  Positive | 334 (50.3) | 40 (70.2) |  | 314 (52.6) | 60 (48.4) |  | 285 (50.0) | 89 (58.9) |  | 347 (51.7) | 27 (54.0) |  |
HER-2 status | Â | Â | 0.876 | Â | Â | 0.004 | Â | Â | 3.072 | Â | Â | 0.001 |
  Negative | 524 (78.9) | 41 (71.9) |  | 480 (80.4) | 85 (68.5) |  | 448 (78.6) | 117 (77.5) |  | 535 (79.7) | 30 (60.0) |  |
  Positive | 140 (21.1) | 16 (28.1) |  | 117 (19.6) | 39 (31.5) |  | 122 (21.4) | 34 (22.5) |  | 136 (20.3) | 20 (40.0) |  |
Ki-67 LI (%) | Â | Â | 0.456 | Â | Â | 3.156 | Â | Â | <0.001 | Â | Â | 1.280 |
  ≤14 | 371 (55.9) | 38 (66.7) |  | 340 (57.0) | 69 (55.6) |  | 303 (53.2) | 106 (70.2) |  | 384 (57.2) | 25 (50.0) |  |
  >14 | 293 (44.1) | 19 (33.3) |  | 257 (43.0) | 55 (44.4) |  | 267 (46.8) | 45 (29.8) |  | 287 (42.8) | 25 (50.0) |  |